Navigation Links
Perrigo Expands Infant Formula Distribution in China With Founder Group
Date:10/19/2011

ALLEGAN, Mich., Oct. 19, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has entered into a supply agreement with Founder Pharma Co., Ltd., a wholly owned subsidiary of publicly listed Southwest Synthetic Pharmaceutical Corp., Ltd. (SZSE: 000788).  Perrigo will supply infant formula manufactured in its U.S. facilities, for sale and distribution by Founder Pharma in China.

Perrigo Chairman and CEO Joseph C. Papa stated, "Southwest Synthetic is an exciting partner given its strong reputation and healthcare focus. Perrigo's high quality products and Southwest Synthetic's strong brand, marketing, and distribution should be a winning combination in the world's most robust infant formula market."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Southwest Synthetic is located in Chongqing, China and is the largest manufacturing, R&D, and exporting enterprise of biological and chemical synthetic pharmaceutical products in southwest China. It is also a key enterprise in China's pharmaceutical industry and is one of China's pharmaceutical enterprises with the most international approvals. In the past 2 to 3 years, it has completed two consolidations and built an industry chain from biological and chemical pharmaceuticals to healthcare products distribution. Visit Southwest Synthetic on the Internet (http://www.fsspc.com/en/)

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
2. Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam
3. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
4. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
5. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
6. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
7. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
8. Perrigo Closes Acquisition of Paddock Labs
9. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
10. Perrigo Provides Update on Acquisition of Paddock Labs
11. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
Breaking Medicine Technology:
(Date:12/2/2016)... Portland, Maine (PRWEB) , ... December 02, 2016 , ... ... support group for caregivers of those affected by autism spectrum disorder (ASD) and other ... and Easter Seals Maine, will give parents and other caregivers the opportunity to share ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, ... Murthy explains how he was inspired to practice medicine at an early age by ... about more than making diagnoses and prescribing medicine,” he states. “It is about building ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” ... living proof that attitude and determination can combine into the most remarkable achievements. ... the holidays. This campaign will offer patients a new-found hope, by seizing the ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
Breaking Medicine News(10 mins):